# Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

> **NCT07481734** · PHASE2 · RECRUITING · sponsor: **Hudson Biotech** · enrollment: 120 (estimated)

## Conditions studied

- Metabolic Associated Steatotic Liver Disease
- Nonalcoholic Steatohepatitis
- Hepatic Steatosis

## Interventions

- **DRUG:** Tesamorelin
- **DRUG:** Placebo
- **BEHAVIORAL:** Standardized lifestyle counseling

## Key facts

- **NCT ID:** NCT07481734
- **Lead sponsor:** Hudson Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-02-14
- **Final completion:** 2028-02-17
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481734, "Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07481734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*